Here are some ways that Chinese active pharmaceutical ingredient manufacturers can enhance their international competitiveness:

Innovation and Quality Improvement
- Increase R&D Investment: Continuously explore new synthesis processes and production technologies to improve API yield and quality. For example, Kexing Biotech has developed enzyme catalysis technology, which increased the yield of a certain anti-cancer drug intermediate to 92%, far higher than the traditional process's 65%.
- Digital Transformation: Build a digital quality system. Utilize big data, cloud computing and other technologies to optimize production processes, improve production efficiency and flexibility. For example, Novartis has adopted AI-driven polymorph prediction technology, shortening the API R&D cycle by 60%.
- Green Manufacturing: Invest in environmental protection facilities and adopt green production processes to reduce carbon emissions and environmental pollution. For example, Prilo Pharmaceutical has invested 320 million yuan to build a photovoltaic - energy storage integrated workshop, reducing carbon emissions per ton of API by 42%.

Industrial Chain Extension and Integration
- Expand into Downstream Formulations: Implement the "API + formulation" integration strategy. Achieve cost reduction through large - scale production, enhance competitiveness in centralized procurement, and then expand into overseas markets. For example, Bioray Medicine started from the API business and gradually established a business model integrating raw materials and formulations, combining generic drugs and innovative drugs.
- Strengthen Supply Chain Management: Build a stable raw material supply system to ensure the continuity and stability of the production process. China occupies about 80% of the global API intermediate market and is the main supplier of intermediates for the United States, Europe and India.

Market Expansion and Strategic Layout
- Global Layout: Establish production bases in developed markets such as Europe and America, obtain local certification, and realize the closed loop of "local production and local sales". For example, Huahai Pharmaceutical has built a factory in Spain and obtained EMA certification.
- Develop Emerging Markets: Establish local distribution centers in emerging markets such as Africa and Latin America to capture market share. For example, CSPC Group has established eight local distribution centers in Africa.
- Participate in International Standard - Setting: Actively participate in the formulation of international pharmaceutical standards to enhance discourse power and influence in the international market.

Cost Control and Competitive Advantage
- Leverage Economies of Scale: China is the world's largest API production base with huge capacity. Cost reduction can be achieved through large - scale production. For example, the cost of producing a certain drug in China is usually 20% lower than that in India, mainly due to cheaper raw materials.
- Policy Support: Take advantage of government subsidies and tax incentives for enterprises to further reduce production costs.

Strengthen International Cooperation and Exchange
- International Cooperation: Establish cooperative relationships with international pharmaceutical companies to jointly carry out R&D and production projects, and absorb international advanced technology and management experience.
- Role of Industry Associations: Strengthen communication and cooperation with international peers through industry associations to jointly deal with international trade frictions and market changes.